CHC

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study

Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, …

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study Read More »

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis

Nahon P, Lusivika-Nzinga C, Merle P, Zoulim F, Decaens T, Ganne-Carrié N, Pageaux GP, Leroy V, Alric L, Bronowicki JP, Bourlière M, Gournay J, Tran A, Pol S, Mathurin P, Loustaud-Ratti V, Métivier S, De Ledinghen V, Abergel A, Thabut D, D’Alteroche L, Bouattour M, Asselah T, Ouzan D, Cales P, Chazouillères O, Gelu-Simeon M, …

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis Read More »

Differences between hepatocellular carcinoma caused by alcohol and other aetiologies

Ganne-Carrié N, Nahon P.J Hepatol. 2024 Dec 20:S0168-8278(24)02817-4. doi: 10.1016/j.jhep.2024.12.030. Online ahead of print. Abstract Alcohol-related liver disease is the third leading cause of hepatocellular carcinoma worldwide and the leading cause in Europe. Additionally, the recent definition of metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD) will enrich this population with a more …

Differences between hepatocellular carcinoma caused by alcohol and other aetiologies Read More »

Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

Nault JC, Sritharan N, Verset G, Borbath I, Lequoy M, Allaire M, Regnault H, Colle I, Orlent H, Sinapi I, Moreno C, Larrey E, Sidali S, Hollande C, Amaddeo G, Pol S, Nahon P, Ganne-Carrié N, Levy V, Bloch-Queyrat C; Paris Liver Cancer Group; Trepo E, Bouattour M.JHEP Rep. 2024 Aug 22;6(11):101192. doi: 10.1016/j.jhepr.2024.101192.  Abstract …

Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study Read More »

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.

Vitellius C, Desjonqueres E, Lequoy M, Amaddeo G, Fouchard I, N’Kontchou G, Canivet CM, Ziol M, Regnault H, Lannes A, Oberti F, Boursier J, Ganne-Carrie N.JHEP Rep. 2024 Jun 29;6(10):101160. doi: 10.1016/j.jhepr.2024.101160. eCollection 2024 Oct.PMID: 39411648  Abstract Background & aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers …

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis. Read More »

EASL position paper on clinical follow-up after HCV cure.

Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, Elsharkawy AM, Forns X.J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6.PMID: 38845253 Review. Abstract Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding …

EASL position paper on clinical follow-up after HCV cure. Read More »

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence.

Boros C, Sutter O, Cauchy F, Ganne-Carrié N, Nahon P, N’kontchou G, Ziol M, Grando V, Demory A, Blaise L, Dondero F, Durand F, Soubrane O, Lesurtel M, Laurent A, Seror O, Nault JC.Liver Int. 2024 Jun;44(6):1464-1473. doi: 10.1111/liv.15900. Epub 2024 Apr 6.PMID: 38581233 Abstract Introduction: We aim to assess the long-term outcomes of percutaneous multi-bipolar radiofrequency (mbpRFA) …

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence. Read More »

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, Noblet B, Nahon P, Hormigos K, Sidali S, Seror O, Taly V, Ganne Carrie N, Laurent-Puig P, Zucman-Rossi J, Nault JC.Gut. 2024 Oct 7;73(11):1870-1882. doi: 10.1136/gutjnl-2024-331956.PMID: 39054058 Abstract Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic …

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Read More »

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC.J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.PMID: 37647991 Background & aims: The “French Medicine Genomic program 2025” has been designed to give patients with cancers …

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Read More »

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. J Hepatol. 2023 Mar;78(3):584-595. doi: 10.1016/j.jhep.2022.11.003. Background & aims: Identifying individuals at higher risk of developing hepatocellular carcinoma (HCC) is pivotal to improve the performance …

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis Read More »